Centre Hospitalier De Libourne Robert Boulin

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Chronic lymphocytic leukaemia1 trial
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 trial
• Multiple myeloma1 trial
• Multiple sclerosis1 trial
• Myeloproliferative neoplasms1 trial

Phase

• Phase 33 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Recruiting3 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Centre Hospitalier Regional Et Universitaire De Brest1 trial
• Dianthus Therapeutics Inc.1 trial
• French Innovative Leukemia Organization (F.I.L.O.).1 trial
• University Hospital, Lille1 trial
• Zenas BioPharma (USA), LLC1 trial

Running trials

• Not yet recruiting

  FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

  2026-525763-40-00· Phase 2· French Innovative Leukemia Organization (F.I.L.O.).· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

  2024-517529-26-00· Phase 3· Dianthus Therapeutics Inc.· Source

• Recruiting

  Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

  2024-515362-13-00· Phase 2/3· Centre Hospitalier Regional Et Universitaire De Brest· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Multiple sclerosis1 recruiting
• Myeloproliferative neoplasms1 recruiting

Closed trials

• Completed

  Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

  NCT03993912· Phase 3· University Hospital, Lille· Source